| 0.3867 0.001 (0.16%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.59 | 1-year : | 0.73 |
| Resists | First : | 0.5 | Second : | 0.63 |
| Pivot price | 0.4  |
|||
| Supports | First : | 0.31 | Second : | 0.25 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.4 |
| MA(100) : | 0.47 |
MA(250) : | 1.1 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 40.2 |
D(3) : | 54.7 |
| RSI | RSI(14): 47.3  |
|||
| 52-week | High : | 3 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OMIC ] has closed above bottom band by 21.2%. Bollinger Bands are 63.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.41 - 0.41 | 0.41 - 0.41 |
| Low: | 0.37 - 0.37 | 0.37 - 0.37 |
| Close: | 0.38 - 0.39 | 0.39 - 0.39 |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Tue, 21 Nov 2023
Singular Genomics Systems Founder Acquires 4.6% More Stock - Yahoo Finance
Tue, 21 Nov 2023
Singular Genomics Systems Founder Acquires 4.6% More Stock - Simply Wall St
Wed, 15 Nov 2023
Singular Genomics Systems, Inc. (NASDAQ:OMIC) Q3 2023 Earnings Call Transcript - Yahoo Finance
Tue, 14 Nov 2023
Similar Genomics Systems: Q3 Earnings Snapshot - Midland Daily News
Tue, 14 Nov 2023
Similar Genomics Systems: Q3 Earnings Snapshot - Quartz
Thu, 09 Nov 2023
Should You Add Singular Genomics Systems Inc (OMIC) Stock to Your Portfolio Thursday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 4.506e+007 (%) |
| Held by Institutions | 13.7 (%) |
| Shares Short | 1,010 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.49e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 311.4 % |
| Return on Equity (ttm) | -19.5 % |
| Qtrly Rev. Growth | 2.6e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -39.74 |
| EBITDA (p.s.) | -24489.8 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.13 |
| Dividend | 0 |
| Forward Dividend | 1.54e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|